Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter J Raubenheimer

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Systematic Reviews|June 8, 2020
The effectiveness of peer and community health worker-led self-management support programs for improving diabetes health-related outcomes in adults in low- and-middle-income countries: a systematic reviewMahmoud Werfalli, Peter J Raubenheimer, Mark Engel, et al.
Diabetes Research and Clinical Practice|June 24, 2021
Risk factors for COVID-19 hospitalisation and death in people living with diabetes: A virtual cohort study from the Western Cape Province, South AfricaJoel A Dave, Tsaone Tamuhla, Nicki Tiffin, et al.
The Journal of Clinical Endocrinology and Metabolism|February 4, 2021
Efficacy and Safety of Dulaglutide in Older Patients: A post hoc Analysis of the REWIND trialMatthew C Riddle, Hertzel C Gerstein, Denis Xavier, et al.
Diabetes, Obesity & Metabolism|January 5, 2022
Dulaglutide and incident atrial fibrillation or flutter in patients with type 2 diabetes: A post hoc analysis from the REWIND randomized trialPeter J Raubenheimer, William C Cushman, Alvaro Avezum, et al.
Cardiovascular Diabetology|August 22, 2022
A novel kidney disease index reflecting both the albumin-to-creatinine ratio and estimated glomerular filtration rate, predicted cardiovascular and kidney outcomes in type 2 diabetesHertzel C Gerstein, Chinthanie Ramasundarahettige, Alvero Avezum, et al.
European Journal of Heart Failure|September 8, 2022
Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post-hoc analysis from the REWIND randomized trialKelley R H Branch, Gilles R Dagenais, Alvaro Avezum, et al.
Cardiovascular Diabetology|November 26, 2020
Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysisGilles R Dagenais, Lars Rydén, Lawrence A Leiter, et al.
The Journal of Clinical Endocrinology and Metabolism|April 21, 2022
Novel Indices of Cognitive Impairment and Incident Cardiovascular Outcomes in the REWIND TrialTali Cukierman-Yaffe, Hertzel C Gerstein, Jan Basile, et al.
The Lancet. Neurology|June 21, 2020
Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trialTali Cukierman-Yaffe, Hertzel C Gerstein, Helen M Colhoun, et al.
The Lancet. Diabetes & Endocrinology|January 12, 2020
The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trialHertzel C Gerstein, Robert Hart, Helen M Colhoun, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Systematic Reviews|June 8, 2020
The effectiveness of peer and community health worker-led self-management support programs for improving diabetes health-related outcomes in adults in low- and-middle-income countries: a systematic reviewMahmoud Werfalli, Peter J Raubenheimer, Mark Engel, et al.
Diabetes Research and Clinical Practice|June 24, 2021
Risk factors for COVID-19 hospitalisation and death in people living with diabetes: A virtual cohort study from the Western Cape Province, South AfricaJoel A Dave, Tsaone Tamuhla, Nicki Tiffin, et al.
The Journal of Clinical Endocrinology and Metabolism|February 4, 2021
Efficacy and Safety of Dulaglutide in Older Patients: A post hoc Analysis of the REWIND trialMatthew C Riddle, Hertzel C Gerstein, Denis Xavier, et al.
Diabetes, Obesity & Metabolism|January 5, 2022
Dulaglutide and incident atrial fibrillation or flutter in patients with type 2 diabetes: A post hoc analysis from the REWIND randomized trialPeter J Raubenheimer, William C Cushman, Alvaro Avezum, et al.
Cardiovascular Diabetology|August 22, 2022
A novel kidney disease index reflecting both the albumin-to-creatinine ratio and estimated glomerular filtration rate, predicted cardiovascular and kidney outcomes in type 2 diabetesHertzel C Gerstein, Chinthanie Ramasundarahettige, Alvero Avezum, et al.
European Journal of Heart Failure|September 8, 2022
Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post-hoc analysis from the REWIND randomized trialKelley R H Branch, Gilles R Dagenais, Alvaro Avezum, et al.
Cardiovascular Diabetology|November 26, 2020
Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysisGilles R Dagenais, Lars Rydén, Lawrence A Leiter, et al.
The Journal of Clinical Endocrinology and Metabolism|April 21, 2022
Novel Indices of Cognitive Impairment and Incident Cardiovascular Outcomes in the REWIND TrialTali Cukierman-Yaffe, Hertzel C Gerstein, Jan Basile, et al.
The Lancet. Neurology|June 21, 2020
Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trialTali Cukierman-Yaffe, Hertzel C Gerstein, Helen M Colhoun, et al.
The Lancet. Diabetes & Endocrinology|January 12, 2020
The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trialHertzel C Gerstein, Robert Hart, Helen M Colhoun, et al.
Pageof 3